Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced a strategic realignment of its resources, discontinuing the development of its CT-0525 program and reducing its workforce by 34%. These decisions are …
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization Read More